Heidelberg Pharma AG
XHAM:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Heidelberg Pharma AG (HPHA) under the Base Case is EUR per share.
Compared with the current market price of 2.01 EUR, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Heidelberg Pharma Does
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin.
- Headquarters
- Germany DE
- Employees
- 60
- IPO date
- Nov 13, 2006
Balance Sheet
Continue HPHA Research
Decided on Heidelberg Pharma? Get an email when HPHA reaches the price you’d buy at. Free with an account.
Other Heidelberg Pharma listings
What is the Intrinsic Value of one HPHA stock?
The intrinsic value for
Heidelberg Pharma AG (HPHA) under the Base Case is EUR.
Is HPHA stock undervalued or overvalued?
Compared with the current market price of 2.01 EUR, the stock appears .